Trials / Not Yet Recruiting
Not Yet RecruitingNCT07464028
Terazosin And Metabolic Energetics in Parkinson's Disease
Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Nandakumar Narayanan · Academic / Other
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study investigates if Terazosin can improve metabolism in PD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Terazosin 5 MG | This drug increases glycolysis in Parkinson's disease. |
| DRUG | Placebo | Placebo control for Terazosin |
Timeline
- Start date
- 2026-07-01
- Primary completion
- 2030-07-01
- Completion
- 2031-07-01
- First posted
- 2026-03-11
- Last updated
- 2026-03-16
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07464028. Inclusion in this directory is not an endorsement.